Literature DB >> 17640316

Heart retransplantation.

M R Johnson1, K D Aaronson, C E Canter, J K Kirklin, D M Mancini, M R Mehra, B Radovancevic, D O Taylor, S A Webber.   

Abstract

Retransplants comprise only a small minority (3-4%) of heart transplants, however outcome following retransplantation is compromised. Risk factors for a poor outcome following retransplantation include retransplantation early (<6 months) after primary transplant, retransplantation for acute rejection or early allograft failure, and retransplantation in an earlier era. The incidence of rejection and infection is similar following primary transplant and retransplantation. The compromised outcomes and risk factors for a poor outcome are similar in adult and pediatric heart retransplantation. However, due to the short half-life of the transplanted heart, it is an expectation that patients transplanted in childhood may require retransplantation. Based on the data available and the opinion of the working group, indications for heart retransplantation are (i) chronic severe cardiac allograft vasculopathy with symptoms of ischemia or heart failure (should be considered) or asymptomatic moderate or severe left ventricular dysfunction (may be considered) or (ii) chronic graft dysfunction with symptoms of progressive heart failure in the absence of active rejection. Patients with graft failure due to acute rejection with hemodynamic compromise, especially <6 months post-transplant, are inappropriate candidates for retransplantation. In addition, guidelines established for primary transplant candidacy should be strictly followed.

Entities:  

Mesh:

Year:  2007        PMID: 17640316     DOI: 10.1111/j.1600-6143.2007.01902.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  9 in total

1.  Inhibition of C-X-C motif chemokine 10 reduces graft loss mediated by memory CD8+ T cells in a rat cardiac re-transplant model.

Authors:  Jiacheng Xu; Teng Ma; Guorong Deng; Jiawei Zhuang; Cheng Li; Shaohu Wang; Chen Dai; Xiaobiao Zhou; Zhonggui Shan; Zhongquan Qi
Journal:  Exp Ther Med       Date:  2017-12-01       Impact factor: 2.447

Review 2.  Management of allosensitized cardiac transplant candidates.

Authors:  Mauricio Velez; Maryl R Johnson
Journal:  Transplant Rev (Orlando)       Date:  2009-10       Impact factor: 3.943

3.  Thalidomide treatment prevents chronic graft rejection after aortic transplantation in rats - an experimental study.

Authors:  Katharine K Miller; Dong Wang; Xiaomeng Hu; Xiaoqin Hua; Tobias Deuse; Evgenios Neofytou; Thomas Renne; Joachim Velden; Hermann Reichenspurner; Sonja Schrepfer; Daniel Bernstein
Journal:  Transpl Int       Date:  2017-08-14       Impact factor: 3.782

Review 4.  Outcomes and survival following heart retransplantation for cardiac allograft failure: a systematic review and meta-analysis.

Authors:  Syed-Saif Abbas Rizvi; Jessica G Y Luc; Jae Hwan Choi; Kevin Phan; Ester Moncho Escrivà; Sinal Patel; H Todd Massey; Vakhtang Tchantchaleishvili
Journal:  Ann Cardiothorac Surg       Date:  2018-01

5.  Heart Retransplant Recipients Have Better Survival With Concurrent Kidney Transplant Than With Heart Retransplant Alone.

Authors:  Jill Savla; Kimberly Y Lin; Madhura Pradhan; Rebecca L Ruebner; Rachel S Rogers; Somaly S Haskins; Anjali T Owens; Peter Abt; J William Gaynor; Robert E Shaddy; Joseph W Rossano
Journal:  J Am Heart Assoc       Date:  2015-12-11       Impact factor: 5.501

Review 6.  Heart Retransplantation: Candidacy, Outcomes, and Management.

Authors:  Maya H Barghash; Sean P Pinney
Journal:  Curr Transplant Rep       Date:  2019-12-17

7.  Nuclear Osteopontin Is a Marker of Advanced Heart Failure and Cardiac Allograft Vasculopathy: Evidence From Transplant and Retransplant Hearts.

Authors:  Camila Iansen Irion; Julian C Dunkley; Krista John-Williams; José Manuel Condor Capcha; Serene A Shehadeh; Andre Pinto; Matthias Loebe; Keith A Webster; Nicolas A Brozzi; Lina A Shehadeh
Journal:  Front Physiol       Date:  2020-08-13       Impact factor: 4.566

8.  miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy.

Authors:  Vera Usuelli; Moufida Ben Nasr; Francesca D'Addio; Kaifeng Liu; Andrea Vergani; Basset El Essawy; Jun Yang; Emma Assi; Mayuko Uehara; Chiara Rossi; Anna Solini; Annalisa Capobianco; Elena Rigamonti; Luciano Potena; Massimo Venturini; Mario Sabatino; Lorena Bottarelli; Enrico Ammirati; Maria Frigerio; Eduardo Castillo-Leon; Anna Maestroni; Cinzia Azzoni; Cristian Loretelli; Andy Joe Seelam; Albert K Tai; Ida Pastore; Gabriella Becchi; Domenico Corradi; Gary A Visner; Gian V Zuccotti; Nelson B Chau; Reza Abdi; Marcus G Pezzolesi; Paolo Fiorina
Journal:  Am J Transplant       Date:  2021-05-03       Impact factor: 9.369

9.  CXCL9 and CXCL10 accelerate acute transplant rejection mediated by alloreactive memory T cells in a mouse retransplantation model.

Authors:  Jiawei Zhuang; Zhonggui Shan; Teng Ma; Chun Li; Shuiwei Qiu; Xiaobiao Zhou; Lianfeng Lin; Zhongquan Qi
Journal:  Exp Ther Med       Date:  2014-05-14       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.